Last reviewed · How we verify

Dunamenti REK Istenhegyi IVF Center — Portfolio Competitive Intelligence Brief

Dunamenti REK Istenhegyi IVF Center pipeline: 4 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Progesterone Progesterone plus HCG marketed Progesterone [EPC] progesterone receptor, luteinizing hormone/choriogonadotropin receptor Metabolic 1978-01-01
higher dose recFSH higher dose recFSH marketed Gonadotropin FSH receptor (FSHR) Reproductive Medicine / Fertility
unchanged dose unchanged dose marketed
no luteal support no luteal support marketed Reproductive Medicine / Fertility

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AGUNCO Obstetrics and Gynecology Centre · 1 shared drug class
  2. Ain Shams Maternity Hospital · 1 shared drug class
  3. Azienda USL Modena · 1 shared drug class
  4. Bezmialem Vakif University · 1 shared drug class
  5. Central Jutland Regional Hospital · 1 shared drug class
  6. D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 shared drug class
  7. El Shatby University Hospital for Obstetrics and Gynecology · 1 shared drug class
  8. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Dunamenti REK Istenhegyi IVF Center:

Cite this brief

Drug Landscape (2026). Dunamenti REK Istenhegyi IVF Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/dunamenti-rek-istenhegyi-ivf-center. Accessed 2026-05-17.

Related